^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Lymphoma |
| Drug: | HZX-02-059 (Tubulin inhibitor, PIKfyve inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma
Published date:
01/28/2022
Excerpt:
Double-hit lymphoma is one of the most aggressive and refractory lymphoma subtypes with recurrent genetic abnormalities of MYC and BCL-2 or BCL6 rearrangement...Here, we reported that HZX-02-059, a novel PIKfyve and tubulin dual-target inhibitor, showed a highly cytotoxic activity against double-hit lymphoma cell lines in vitro and in vivo...In summary, the present findings suggest that HZX-02-059 represents a good starting point for developing targeted therapeutics against double-hit lymphomas.
DOI:
10.1038/s41420-022-00833-9
